These promising results were confirmed in vivo: significant inhibition of tumor growth by rogaratinib (a potent and selective FGFR1–4 inhibitor) was observed in two patient-derived xenografts (PDX) (LU299–Sq-NSCLC and LXFL1121-NSCLC) overexpressing FGFR1 mRNA but not harboring high FGFR amplification (58). This evidence concerns the gene FGFR1 and neoplasm.